Evidence map›Paper›PMID 32678528›Full record

ArticleThe New England journal of medicine2021

Research in the Context of a Pandemic.

H Clifford Lane, Anthony S Fauci

Abstract readEditorialComment
In one paragraph

Article in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.American journal of respiratory and critical care medicine · 2023
    Article
  5. Review
  6. COVID-19: Vaccines and therapeutics.Bioorganic & medicinal chemistry letters · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Is rapid scientific publication also high quality? Bibliometric analysis of highly disseminated COVID-19 research papers.Learned publishing : journal of the Association of Learned and Professional Society Publishers · 2021
    Article
  14. Review
  15. Review
  16. Coronavirus disease 2019 and clinical research in U.S. nursing homes.Journal of the American Geriatrics Society · 2021
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

H Clifford LaneFrom the Division of Clinical Research (H.C.L.) and Office of the Director (A.S.F.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-9509-1045
Anthony S FauciFrom the Division of Clinical Research (H.C.L.) and Office of the Director (A.S.F.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Funding

Pathogenesis, Treatment and Prevention of Emerging Infectious DiseasesZIAAI000936 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LANE, CLIFFORD · 2009 to 2025
$6.4M
Medical Research Council MC_PC_19056
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentPandemicsDexamethasoneHumansSARS-CoV-2Dexamethasone

Identifiers

PMID32678528
PMCPMC7383591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.